ArticleOrphanet journal of rare diseases2021

Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England.

Maureen Cleary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.